[COVID-19 vaccines and specific drugs help double Pfizer's revenue and profit in 2021] Pfizer achieved a total of $81.3 billion in revenue and $25.2 billion in net profit (adjusted

Pfizer doubled revenue and profit in 2021 with $81.3 billion in revenue and $25.2 billion in net profit (adjusted), both of which nearly doubled year-on-year.

The biggest drivers of performance were covid-19 vaccines (Pfizer-BioNTech, market-named COMIRNATY) and the covid-19 oral drug Paxlovid, which together contributed $36.8 billion in revenue. As the epidemic continues and vaccination rates increase further, Pfizer predicts that vaccine sales revenue will reach $32 billion this year.

Paxlovid is also the first approved ORAL COVID-19 drug, which, according to Pfizer experimental data, can reduce the risk of severe illness by 89%, far exceeding its peers, and is considered safer and recommended for priority use. After being approved on December 23 last year, it earned $76 million in less than ten days. As subsequent orders continue to rise, Pfizer predicts it will bring in $22 billion in revenue this year.

Pfizer is also working on new COVID-19 drugs, including a vaccine for Omicron, which launched clinical trials late last month, and is expected to launch in March.

After the results were released, Pfizer shares fell 5% at one point. Common explanations are performance that falls short of Wall Street's consensus expectations, and market concerns that business growth is too dependent on COVID-19 drugs — which may not be sustainable.

Pfizer invested $13.829 billion in research and development in 2021, up 47% year-on-year, and forecasts revenue to grow to $98-102 billion next year. Its business also includes cardiovascular, cancer, internal medicine drugs and so on. Pfizer said on the conference call that it is now more inclined to strengthen its own research and development capabilities than past mergers and acquisitions, which will provide better development momentum for the company. (Lin Guangying) #辉瑞2021年营收入813亿美元, the new crown vaccine contributed $36.78 billion in revenue #